January 15, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta and Shire Agree to Merge in $32 Billion Deal The boards

Source URL: www.dcat.org

January 8, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Baxalta, Symphogen Ink $1.6 Billion Immuno­Oncology Deal In yet

Source URL: www.dcat.org

• Business
• Biotechnology
• Economy
• Pharmacy
• Pharmaceutical industry
• Pharmaceuticals policy
• Biopharmaceutical
• Pharmaceutical industry in India
• Novartis
• Biosimilar
• Boehringer Ingelheim
• Teva Pharmaceutical Industries

Gemäß den Richtlinien des FSA- oder anderer Kodizes legen wir hier die finanzielle Unterstützung der Mitglieder offen: Baxalta Deutschland GmbH Ausstellungsstand, weitere Werbeleistungen, 1.150,00 € Bayer Vital GmbH

Source URL: www.mitteldeutsche-laborkonferenz.de

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology  Partnership aims to advance development of novel immune checkpoint

Source URL: sunstone.eu

UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •

Source URL: www.nektar.com

• Blood
• Coagulation system
• Biology
• Recombinant proteins
• Baxalta
• Von Willebrand disease
• Haemophilia
• Factor VIII
• PEGylation
• Baxter International
• Factor VII
• Recombinant factor VIIa